Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 1, 2008, Pages 1-5

  Cohen, Steven J ^a   Engstrom, Paul F ^a   Lewis, Nancy L ^a   Langer, Corey J ^a   McLaughlin, Susan ^a   Beard, Mary ^a   Weiner, Louis M ^a   Meropol, Neal J ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Bortezomib; Capecitabine; Oxaliplatin; Proteasome inhibitor

Indexed keywords

ANTIEMETIC AGENT; BORTEZOMIB; CAPECITABINE; DEXAMETHASONE; FLUOROURACIL; MITOMYCIN C; OXALIPLATIN; SEROTONIN 3 ANTAGONIST; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; DEOXYCYTIDINE; DRUG DERIVATIVE; PLATINUM COMPLEX; PYRAZINE DERIVATIVE;

ADENOCARCINOMA; ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANUS CANCER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LEUKOPENIA; LIVER CELL CARCINOMA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; RECTUM CARCINOMA; SIDE EFFECT; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; COHORT ANALYSIS; DOSE RESPONSE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COHORT STUDIES; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PYRAZINES;

EID: 42449094627     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31805c142f     Document Type: Article

References (27)

1. Adams J. Development of the proteasome inhibitor PS-341. Oncologist. 2002;7:9-16.
2. Rajkumar SV, Richardson PG, Hideshima T, et al. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005;23: 630-639.
3. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615-2622.
4. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 2002;8:2505-2511.
5. Hamilton AL, Eder JP, Pavlick AC, et al. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol. 2005;23:6107-6116.
6. Shields AF, Zalupski MM, Marshall JL, et al. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. Cancer. 2004;100:531-537.
7. Jatoi A, Murphy BR, Foster NR, et al. Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol. 2006;17:29-34.
8. Glover KY, Thomas MB, Brown TD, et al. A phase II study of oxaliplatin and capecitabine (XELOX) in patients with unresectable cholangiocarcinoma, including carcinoma of the gallbladder and biliary tract. Proc Am Soc Clin Oncol. 2005;4123.
9. Kubicka S, Arkenaw H, Grothey A, et al. Randomized trial of infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): final results of the safety and efficacy analysis. Gastrointest Cancer Symp. 2006:277.
10. Arkenau H, Schmoll H, Kubicka S, et al. Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer (MCRC): results of the safety and efficacy analysis. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol. 2005;23(suppl):3507.
11. Lind DS, Hochwald SN, Malaty J, et al. Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery. 2001;130:363-369.
12. Scaife CL, Kuang J, Wills JC, et al. Nuclear factor kappaB inhibitors induce adhesion-dependent colon cancer apoptosis: implications for metastasis. Cancer Res. 2002;62:6870-6878.
13. Chuang SE, Yeh PY, Lu YS, et al. Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem Pharmacol. 2002;63:1709-1716.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
15. Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): final analysis of the TREE-Study. 2006 ASCO Annual Meeting Proceedings. J Clin Oncol. 2006;24(suppl):3510.
16. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24: 3113-3120.
17. Grothey A. Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer. 2005;5(suppl 1):38-46.
18. Rodel C, Grabenbauer GG, Papadopoulos T, et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol. 2003;21:3098-3104.
19. Mackay H, Hedley D, Major P, et al. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res. 2005;11:5526-5533.
20. Dragovich T, Lenz HJ, Rocha Lima CMS, et al. Bortezomib ± irinotecan in relapsed/refractory colorectal cancer (CRC): interim analysis results from phase (ph) 2b study. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol. 2004;22(suppl):3591.
21. Cusack JC Jr, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res. 2001;61:3535-3540.
22. Ryan DP, O'Neil BH, Supko JG, et al. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer. 2006; 107:2688-2697.
23. Ocean AJ, Schnoll-Sussman F, Chen X, et al. Phase II study of PS-341 (VELCADE, bortezomib) with or without irinotecan in patients with advanced gastric adenocarcinomas (AGA). Proc Gastrointest Cancer Symp. 2005;31.
24. Ocean AJ, Schnoll-Sussman F, Keresztes R, et al. Phase II study of PS-341 (bortezomib) with or without irinotecan in patients with advanced gastric adenocarcinomas (AGA). 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2006;24(suppl):14040.
25. Sumpter K, Harper-Wynne C, Cunningham D, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer. 2005;92:1976-1983.
26. Chen RF, Li ZH, Kong XH, et al. Effect of mutated IkappaBalpha transfection on multidrug resistance in hilar cholangiocarcinoma cell lines. World J Gastroenterol. 2005;11:726-728.
27. Liu X, Zou S, Qiu F. Expression of nuclear factor kappa B in hepatitis C virus core gene transfected cholangiocarcinoma cells. Chin Med J(Engl). 2002;115:998-1001.